Reversible Airway Diseases Treatment Market Report 2026

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $90.91 billion in 2025 to $96.83 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing prevalence of asthma and bronchitis, expansion of pulmonary care infrastructure, availability of inhalation therapies, rising environmental pollution levels, improved access to diagnostic imaging.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $128.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing focus on biologic respiratory drugs, rising adoption of remote patient monitoring, expansion of minimally invasive pulmonary procedures, growing emphasis on preventive respiratory care, increasing investment in respiratory disease research. Major trends in the forecast period include increasing adoption of personalized respiratory therapies, rising use of advanced diagnostic imaging, growing focus on early disease detection, expansion of combination drug therapies, enhanced integration of digital pulmonary monitoring.

The increasing incidence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market in the coming years. Respiratory diseases are medical conditions that affect the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Chronic respiratory disease testing and treatment support early detection and accurate diagnosis of conditions such as acute respiratory distress syndrome and help prevent disease progression by reducing the risk of complications. For example, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England rose by 10.7% in 2023, increasing from 4,380 cases in 2022 to 4,850 cases. This highlights a significant rise in TB incidence over the year. Therefore, the growing burden of chronic respiratory diseases is driving the growth of the reversible airway disease treatment market.

Major companies operating in the reversible airway disease treatment market are concentrating on the development of advanced digital sensor solutions to improve patient monitoring and overall care delivery. Digital sensor technologies capture real-time physiological data and medication usage information, enabling healthcare providers to remotely monitor inhaler adherence and usage technique. For instance, in March 2023, Adherium Limited, an Australia-based digital health company, received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation Hailie sensor integrated with Teva’s ProAir HFA and Albuterol Sulphate inhalers. The Hailie sensor delivers detailed insights into inhaler usage and physiological metrics, allowing physicians to track both maintenance and rescue medication use. It provides real-time feedback on inhaler technique, supports informed clinical decision-making, and enables remote patient monitoring under U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement codes. The solution is compatible with multiple inhalers, covers a large share of leading U.S. branded medications, and integrates with mobile and desktop platforms, offering a drug-agnostic approach to enhanced respiratory disease management.

In February 2024, GSK plc, a UK-based pharmaceutical and vaccine company, acquired Aiolos Bio Inc. for $1.4 billion. Through this acquisition, GSK aims to strengthen its respiratory portfolio by gaining access to innovative asthma therapies, thereby reinforcing its position in the reversible airway disease treatment market. Aiolos Bio Inc. is a US-based company focused on the development of novel treatments for asthma.

Major companies operating in the reversible airway diseases treatment market are Pfizer Inc., F Hoffmann La Roche AG, Merck And Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline Plc, Medtronic plc, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Sun Pharmaceutical Industries Ltd, Drägerwerk AG And Co KGaA, Dr Reddys Laboratories Ltd, Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher And Paykel Healthcare Corporation Limited, AstraZeneca Plc, Chiesi Farmaceutici SpA.

North America was the largest region in the reversible airway diseases treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the reversible airway diseases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the reversible airway diseases treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the reversible airway diseases treatment market by increasing costs of imported imaging equipment, inhalation devices, diagnostic tools, and pharmaceutical manufacturing inputs. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces higher treatment equipment costs. These tariffs are contributing to increased treatment expenses and delayed equipment procurement. However, they are also encouraging local production of respiratory devices, domestic pharmaceutical manufacturing, and regional innovation in cost-effective treatment solutions.

The reversible airway diseases treatment market research report is one of a series of new reports that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities, and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Reversible airway diseases are conditions marked by temporary narrowing of the airways, usually caused by inflammation and contraction of the surrounding smooth muscles. The primary objective of treatment for these conditions is to alleviate symptoms such as cough and wheezing and to improve overall lung function.

The main types of treatment for reversible airway diseases include chest X-rays, computed tomography (CT) scans, lung therapies, surgical transplants, and medications. A chest X-ray is a diagnostic imaging method that uses a low dose of ionizing radiation to produce images of the chest structures, including the lungs, heart, and bones. The conditions treated include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatments are utilized by various end users such as hospitals, specialty clinics, and others.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.